

Supplementary Table 3. Evidence table about the eradication rate of standard triple therapy in *H. pylori* infection

Study	Indication	Subjects No.	Eradication regimen	Confirmative test	Eradication rate ITT	Eradication rate PP
Choi (2007)	PU, NUD	576	OAC7-148	CLO, histology	OAC7-64.9 (96/148)	OAC7-80.7 (96/119)
			PAC7-140		PAC7-69.3 (97/140)	PAC7-76.9 (97/121)
			RAC7-140		RAC7-69.3 (97/140)	RAC7-81.5 (97/119)
			EAC7-148		EAC7-70.3 (104/148)	EAC7-82.6 (104/121)
			TOTAL-576		TOTAL-68.4 (394/576)	TOTAL-82.1 (394/480)
Kim (2007)	PU	598	PAC7-337 PAC14-261	UBT	PAC7-71.2 (240/337) PAC14-75.5 (197/261)	PAC7-83.6 (239/286) PAC14-86.6 (194/224)
Kim (2008)	PU	463	LFT7-115	UBT	LFT7-76.5 (88/115)	LFT7-81.6 (80/98)
			LFT14-117		LFT14-76.9 (90/117)	LFT14-82.0 (73/89)
			LAC7-119		LAC7-78.2 (93/119)	LAC7-82.2 (83/101)
			LAC14-112		LAC14-80.4 (90/112)	LAC14-85.9 (79/92)
Kim (2008)	PUD, NUD	186	OAC14-93 OAC(QID)14-93	UBT, CLO	OAC14-91.4 (85/93) OAC(QID)14-89.2 (83/93)	OAC14-92.1 (82/89) OAC(QID)14-90.8 (79/87)
			Kim (2008)		HP infected patients	347
Choi (2008)	HP infected patients	158	OAC7-81 SEQ10-77	UBT	OAC7-71.6 (58/81) SEQ10-77.9 (60/77)	OAC7-76.6 (58/76) SEQ10-85.7 (60/70)
Jung (2008)	PUD	38	OAC7+O3WK-14	CLO, histology	OAC7+O3WK-14-50.0 (7/14)	OAC7+O3WK-87.5 (7/8)
			OAC7-12		OAC7-12-66.7 (8/12)	OAC7-80.0 (8/10)
			O3WK+OAC7-12		O3WK+OAC7-75.0 (9/12)	O3WK+OAC7-90.0 (9/10)
Kim (2008)	HP infected patients	257	LAC7-129 LAC7+ECABET-128	UBT	LAC7-72.1 (93/129) LAC7+ECABET-78.9 (101/128)	LAC7-78.8 (93/118) LAC7+ECABET-88.6 (101/114)
			Song (2010)		HP infected patients	991
Lee (2010)	HP infected patients	492	LAC7-247 RAC7-245	UBT	LAC7-74.9 (185/247) RAC7-66.5 (163/245) TOTAL-70.7 (348/492)	LAC7-79.1 (185/234) RAC7-71.2 (163/229) TOTAL-75.2 (348/463)
Kim (2011)	HP infected patients	409	PAC14-204 SEQ10-205		PAC14-75.0 (153/204) SEQ10-85.9 (176/205)	PAC14-85.0 (153/180) SEQ10-92.6 (176/190)
Choi (2011)	PUD	363	OAC7-99		OAC7-77.8 (77/99)	OAC7-85.6 (77/90)
			OAL7-98		OAL7-65.3 (64/98)	OAL7-73.6 (64/87)
			OALR7-98		OALR7-74.5 (73/98)	OALR7-80.2 (73/91)
Chung (2012)	PUD	159	OAC10-80 SEQ10-79		OAC10-58.7 (47/80) SEQ10-75.9 (60/79)	OAC10-67.6 (46/68) SEQ10-86.8 (59/68)
			Choi (2012)	PUD	460	RAC7-115 RAC10-115 RAC14-115 SEQ10-115

Supplementary Table 3. Continued

Study	Indication	Subjects No.	Eradication regimen	Confirmative test	Eradication rate ITT	Eradication rate PP
Park (2012)	HP infected patients	348	SEQ10-162 RAC7-164		SEQ10-77.8 (126/162) RAC7-62.2 (102/164)	SEQ10-87.9 (126/132) RAC7-76.0 (102/125)
Oh (2012)	PUD, HP infected patients	246	SEQ10-116 RAC7-130		SEQ10-79.3 (92/116) RAC7-63.0 (82/130)	SEQ10-81.9 (91/111) RAC7-64.5 (82/127)
Kim (2012)	PUD	208	LAC14-104 LA(TID)14-104	UBT, CLO	LAC14-74.0 (77/104) LA(TID)14-67.3 (70/104)	LAC14-82.8 (77/93) LA(TID)14-78.4 (69/88)
Lee (2013)	PUD	1232	TAILORED-218 RAC7-308 RAM7-308	UBT	TAILORED-80.7 (176/218) RAC7-69.5 (214/308) RAM7-71.1 (219/308)	TAILORED-91.2 (176/193) RAC7-75.9 (214/282) RAM7-79.1 (219/277)
Kim (2013)	PUD	270	LAC7-135 CONCO5-135	UBT	LAC7-72.6 (98/135) CONCO5-80.7 (109/135)	LAC7-85.2 (98/115) CONCO5-91.4 (106/116)
Heo (2014)	PUD	348	LAC10-174 CONCO10-174	UBT	LAC10-70.7 (123/174) CONCO10-78.7 (137/174)	LAC10-78.4 (120/153) CONCO10-88.7 (133/150)
Park (2014)	EGC, dysplasia	114	PAC7-57 PRE-SUSCEP-57	UBT	PAC7-71.9 (41/57) PRE-SUSCEP-94.7 (54/57)	PAC7-73.2 (41/56) PRE-SUSCEP-96.4 (54/56)
Lee (2014)	PUD, NUD, GC	332	PAC7-115 SEQ10-111 SEQ15-106	UBT, CLO	PAC7-64.3 (74/115) SEQ10-72.1 (80/111) SEQ15-80.2 (85/106)	PAC7-68.5 (74/108) SEQ10-78.4 (80/102) SEQ15-89.5 (85/95)
Lee (2015)	PUD, HP gastritis	680	PAC7-170 PAM7-170 SEQ10-170 CONCO7-170	UBT	PAC7-64.1 (109/170) PAM7-68.8 (117/170) SEQ10-70.7 (119/170) CONCO7-79.4 (135/170)	PAC7-76.2 (109/143) PAM7-84.2 (117/139) SEQ10-70.7 (119/170) CONCO7-79.4 (135/170)
Bang (2015)	PUD, NUD	112	PAC7-55 PAC7+PRONASE-57	UBT	PAC7-76.4 (42/55) PAC7+PRONASE-56.1 (32/57)	PAC7-87.5 (42/48) PAC7+PRONASE-68.1 (32/47)
Chung (2016)	PUD, EGC, MALT lymphoma	517	PAC10-171 SEQ10-170 CONCO10-176		PAC10-83.0 (142/171) SEQ10-88.8 (151/170) CONCO10-93.2 (164/176)	PAC10-82.8 (106/128) SEQ10-89.5 (119/133) CONCO10-94.4 (135/143)
Kim (2016)	PUD	601	PAC7-295 SEQ5-306	UBT, CLO, histology	PAC7-70.8 (209/295) SEQ5-82.4 (252/306)	PAC7-76.9 (206/268) SEQ5-88.8 (247/278)

ITT, intention-to-treat; PP, per protocol; PU, peptic ulcer; NUD, non-ulcer dyspepsia; OAC, omeprazole, amoxicillin, clarithromycin; PAC, pantoprazole, amoxicillin, clarithromycin; RAC, rabeprazole, amoxicillin, clarithromycin; EAC, esomeprazole, amoxicillin, clarithromycin; CLO, campylobacter-like organism; UBT, urea breath test; LFT, lifabutin; PUD, peptic ulcer disease; QID, quarter in die; HP, *Helicobacter pylori*; YOGT, yogurt; SEQ, sequential therapy; O3WK, omeprazole 3 weeks; ECABET, ecabet sodium; PROB, probiotics; OALR, omeprazole, amoxicillin, levofloxacin, rifabutin; LA, levofloxacin, amoxicillin; TID, ter in die; RAM, rabeprazole, amoxicillin, metronidazole; CONCO, concomitant therapy; EGC, early gastric cancer; PRE-SUSCEP, pre-susceptibility test; GC, gastric cancer; PAM, pantoprazole, amoxicillin, metronidazole; MALT, mucosa-associated lymphoid tissue.